Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $.01 per share
-
Shares outstanding
-
7,035,714
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
1,141,975
-
Shares change
-
+495,464
-
Total reported value, excl. options
-
$10,140,752
-
Value change
-
+$4,400,867
-
Number of buys
-
10
-
Number of sells
-
3
-
Price
-
$8.88
Institutional Holders of Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) as of Q4 2024
As of 31 Dec 2024 Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) had 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 1,141,975 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Alyeska Investment Group, L.P., Ikarian Capital, LLC, Vestal Point Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, and MILLENNIUM MANAGEMENT LLC.
This table shows 17 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.